Skip to main content

Advertisement

Log in

Imaging of the dopaminergic system in differential diagnosis of dementia

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Neurodegenerative dementia is an increasingly common disorder with Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) accounting for most cases. Due to the overlap in clinical symptoms, their differential diagnosis may be challenging. As clinical classification is not completely satisfying, there is a need to improve the diagnostic accuracy by complementary methods such as functional single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. The latter may be helpful to address one distinct biological difference between DLB and AD, the severe nigrostriatal degeneration which occurs in DLB, but not to any significant extent in AD. Based on this principle, autoradiographic studies targeting presynaptic dopaminergic functions have consistently demonstrated the ability to distinguish DLB from AD in postmortem series. At the same time, several single-site and one multicentre study have independently confirmed—no matter what technique was used (SPECT or PET) and which presynaptic function was addressed (dopamine turnover, dopamine transporter, vesicular monoamine transporter)—significantly compromised scan results in DLB subjects, whereas AD patients maintained almost normal findings. Even more important, in vivo findings of presynaptic dopaminergic imaging correlated well with neuropathological findings at autopsy, suggesting a remarkable sensitivity of 88% and a specificity of 100% for the imaging procedure to distinguish between DLB and AD. Taken together, imaging of presynaptic dopaminergic terminal functions with SPECT and PET has currently the greatest evidence base to support its use, and therefore, may be highly recommended to help in the discrimination between DLB and AD. Compared to presynaptic functions, corresponding data targeting postsynaptic dopamine receptors are comparatively rare, less conclusive and suggest a very limited role for this purpose. This review discusses the findings of studies specifically dealing with imaging of the dopaminergic system in the differential diagnosis of dementia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol 2004;3:19–28.

    Article  PubMed  Google Scholar 

  2. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–13.

    Article  PubMed  Google Scholar 

  3. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1–26.

    Article  PubMed  CAS  Google Scholar 

  4. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–53.

    PubMed  CAS  Google Scholar 

  5. McKeith IG, Fairbairn AF, Perry RH, Thompson P. The clinical diagnosis and misdiagnosis of senile dementia of Lewy body type (SDLT). Br J Psychiatry 1994;165:324–32.

    Article  PubMed  CAS  Google Scholar 

  6. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 1999;122(Pt 8):1449–68.

    Article  PubMed  Google Scholar 

  7. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 2002;51:767–71.

    Article  PubMed  Google Scholar 

  8. Donnemiller E, Heilmann J, Wenning GK, Berger W, Decristoforo C, Moncayo R, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320–5.

    PubMed  CAS  Google Scholar 

  9. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30–5.

    Article  PubMed  CAS  Google Scholar 

  10. Walker Z, Costa DC, Ince P, McKeith IG, Katona CL. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 1999;354:646–7.

    Article  PubMed  CAS  Google Scholar 

  11. Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson’s disease. Eur J Nucl Med 2001;28:1523–8.

    Article  PubMed  CAS  Google Scholar 

  12. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134–40.

    Article  PubMed  CAS  Google Scholar 

  13. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004;62:1568–72.

    PubMed  CAS  Google Scholar 

  14. Ceravolo R, Volterrani D, Gambaccini G, Rossi C, Logi C, Manca G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer’s disease. Neurol Sci 2003;24:162–3.

    Article  PubMed  CAS  Google Scholar 

  15. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919–25.

    Article  PubMed  Google Scholar 

  16. Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer’s disease and Parkinson's disease. Neuroimage 2004;23:956–66.

    Article  PubMed  Google Scholar 

  17. Costa DC, Walker Z, Walker RW, Fontes FR. Dementia with Lewy bodies versus Alzheimer’s disease: role of dopamine transporter imaging. Mov Disord 2003;18(Suppl 7):S34–38.

    Article  PubMed  Google Scholar 

  18. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with lewy bodies: A comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176–81.

    Article  PubMed  Google Scholar 

  19. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000;55:1575–7.

    PubMed  CAS  Google Scholar 

  20. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer’s disease. Ann Neurol 2004;55:774–80.

    Article  PubMed  Google Scholar 

  21. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:609–14.

    PubMed  CAS  Google Scholar 

  22. Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677–92.

    Article  PubMed  CAS  Google Scholar 

  23. Kemppainen N, Ruottinen H, Nagren K, Rinne JO. PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD. Neurology 2000;55:205–9.

    PubMed  CAS  Google Scholar 

  24. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007;28:511–9.

    Article  PubMed  Google Scholar 

  25. Herholz K. PET studies in dementia. Ann Nucl Med 2003;17:79–89.

    Article  PubMed  Google Scholar 

  26. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594–607.

    PubMed  Google Scholar 

  27. Van Heertum RL, Tikofsky RS. Positron emission tomography and single-photon emission computed tomography brain imaging in the evaluation of dementia. Semin Nucl Med 2003;33:77–85.

    Article  PubMed  Google Scholar 

  28. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718–25.

    Article  PubMed  CAS  Google Scholar 

  29. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.

    Article  PubMed  CAS  Google Scholar 

  30. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 2005;46:936–44.

    PubMed  CAS  Google Scholar 

  31. Taylor JP, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish AD from DLB. J Neurol Neurosurg Psychiatry 2007;78:1069–71.

    Article  PubMed  Google Scholar 

  32. Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006;44:1472–80.

    Article  PubMed  CAS  Google Scholar 

  33. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 2007;260:33–7.

    Article  PubMed  Google Scholar 

  34. Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2006;33:248–53.

    Article  PubMed  Google Scholar 

  35. Firbank MJ, Blamire AM, Krishnan MS, Teodorczuk A, English P, Gholkar A, et al. Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer’s disease. Psychiatry Res 2007;155:135–45.

    Article  PubMed  Google Scholar 

  36. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, et al. 1H MR spectroscopy in common dementias. Neurology 2004;63:1393–8.

    PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

There are no conflicts of interest for the author.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Klaus Tatsch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tatsch, K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging 35 (Suppl 1), 51–57 (2008). https://doi.org/10.1007/s00259-007-0702-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0702-0

Keywords

Navigation